Teleflex - TFX Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Teleflex in the last twelve months. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TFX shares.
View TFX analyst ratings or view top-rated stocks.

12 equities research analysts have issued 12 month target prices for Teleflex's stock. Their TFX share price forecasts range from $210.00 to $330.00. On average, they anticipate the company's stock price to reach $271.69 in the next year. This suggests a possible upside of 9.1% from the stock's current price.
View analysts price targets for TFX or view top-rated stocks among Wall Street analysts.

Teleflex's stock was trading at $249.63 at the beginning of 2023. Since then, TFX shares have decreased by 0.3% and is now trading at $248.93.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our TFX earnings forecast.

Teleflex Incorporated (NYSE:TFX) announced its quarterly earnings results on Thursday, February, 23rd. The medical technology company reported $3.52 EPS for the quarter, beating analysts' consensus estimates of $3.44 by $0.08. The medical technology company earned $758 million during the quarter, compared to analyst estimates of $760.29 million. Teleflex had a net margin of 13.01% and a trailing twelve-month return on equity of 15.87%. Teleflex's revenue for the quarter was down .5% compared to the same quarter last year. During the same period in the prior year, the company earned $3.60 earnings per share.
Read the conference call transcript.

Teleflex announced a quarterly dividend on Thursday, February 23rd. Shareholders of record on Friday, March 3rd will be given a dividend of $0.34 per share on Wednesday, March 15th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date is Thursday, March 2nd.
Read our dividend analysis for TFX.

ETFs with the largest weight of Teleflex (NYSE:TFX) stock in their portfolio include First Trust Indxx Medical Devices ETF (MDEV), SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P 500 Equal Weight Health Care ETF (RYH), iShares U.S. Medical Devices ETF (IHI), Principal Quality ETF (PSET), First Trust Mid Cap US Equity Select ETF (RNMC), Global X Aging Population ETF (AGNG) and First Trust Health Care AlphaDEX Fund (FXH).

Teleflex (NYSE:TFX) pays an annual dividend of $1.36 per share and currently has a dividend yield of 0.56%. The dividend payout ratio is 17.71%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TFX will have a dividend payout ratio of 9.30% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TFX.

Teleflex updated its FY23 earnings guidance on Thursday, February, 23rd. The company provided earnings per share guidance of $13.00-13.60 for the period, compared to the consensus earnings per share estimate of $13.49. The company issued revenue guidance of ~$2.91-2.95 billion, compared to the consensus revenue estimate of $2.92 billion.

73 employees have rated Teleflex Chief Executive Officer Liam Kelly on Glassdoor.com. Liam Kelly has an approval rating of 86% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teleflex investors own include NVIDIA (NVDA), AbbVie (ABBV), Johnson & Johnson (JNJ), Alibaba Group (BABA), Lam Research (LRCX), ServiceNow (NOW), QUALCOMM (QCOM), Advanced Micro Devices (AMD), Salesforce (CRM) and Cisco Systems (CSCO).

Teleflex trades on the New York Stock Exchange (NYSE) under the ticker symbol "TFX."

Teleflex's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include T. Rowe Price Investment Management Inc. (18.40%), Morgan Stanley (5.74%), Price T Rowe Associates Inc. MD (2.60%), Geode Capital Management LLC (2.02%), Allspring Global Investments Holdings LLC (1.71%) and Bessemer Group Inc. (1.13%). Insiders that own company stock include Andrew A Krakauer, Cameron P Hicks, John Deren, Liam Kelly, Stephen K MD Klasko, Stephen K MD Klasko and Stuart A Randle.
View institutional ownership trends.

Shares of TFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TFX stock can currently be purchased for approximately $248.93.

Teleflex (NYSE:TFX) has a market capitalization of $11.68 billion and generates $2.79 billion in revenue each year. The medical technology company earns $363.14 million in net income (profit) each year or $7.68 on an earnings per share basis.

The company employs 15,500 workers across the globe.

Teleflex's mailing address is 550 E SWEDESFORD RD, WAYNE PA, 19087. The official website for the company is www.teleflex.com. The medical technology company can be reached via phone at (610) 225-6800, via email at shareholder@broadridge.com, or via fax at 215-553-5402.